Uncategorized

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update Read More »

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited announces the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease.

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease Read More »

Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company’s Quality Management System

Ascentage Pharma announced that it recently received a zero-deficiency report from the GMP compliance audit of Ascentage Pharma’s Global Manufacturing Center by a Qualified Person of the European Union.

Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company’s Quality Management System Read More »

Scroll to Top